Video
Current clinical trials examining LuPSMA
Author(s):
“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Video Player is loading.
In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the current clinical trials highlighted in the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat. Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.
Related Videos
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Expert: PSMA-PET should be considered at lower PSA levels
Related Content
